Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer:  results of a multicenter observational study in the Russian Federation

E. V. Borodavina; Бородавина Е. В.; P. A. Isaev; Исаев П. А.; A. Yu. Shurinov; Шуринов А. Ю.; P. O. Rumyantsev; Румянцев П. О.; V. V. Krylov; Крылов В. В.; K. M. Petrosyan; Петросян К. М.; A. D. Kaprin; Каприн А. Д.; S. A. Ivanov; Иванов С. А.; S. O. Podvyaznikov; Подвязников С. О.; I. S. Romanov; Романов И. С.; A. M. Mudunov; Мудунов А. М.; K. Yu. Slashchuk; Слащук К. Ю.; R. S. Zhikhorev; Жихорев Р. С.; M. V. Volkonsky; Волконский М. В.; R. M. Chagova; Чагова Р. М.; I. R. Suslova; Суслова И. Р.; A. I. Khryapa; Хряпа А. И.; A. Kh. Lepshokova; Лепшокова А. Х.; N. L. Fadeeva; Фадеева Н. Л.; A. R. Safarova; Сафарова А. Р.; L. P. Kaleykina; Калейкина Л. П.; E. V. Lymar; Лымарь Е. В.; E. M. Chernyakova; Чернякова Е. М.; O. A. Snezhko; Снежко О. А.; A. E. Zinkovskaya; Зиньковская А. Е.; F. F. Mufazalov; Муфазалов Ф. Ф.; E. S. Kuzmina; Кузьмина Е. С.; Yu. V. Druzhinina; Дружинина Ю. В.; Sh. I. Musin; Мусин Ш. И.; M. R. Mukhitova; Мухитова М. Р.; A. I. Khasanova; Хасанова А. И.; S. Z. Safina; Сафина С. З.; S. L. Kirienko; Кириенко С. Л.

doi:10.17650/2222-1468-2020-10-1-65-72

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation

Authors: Borodavina E.V.¹, Isaev P.A.¹, Shurinov A.Y.¹, Rumyantsev P.O.², Krylov V.V.¹, Petrosyan K.M.¹, Kaprin A.D.¹, Ivanov S.A.¹, Podvyaznikov S.O.³, Romanov I.S.⁴, Mudunov A.M.⁴, Slashchuk K.Y.², Zhikhorev R.S.⁵, Volkonsky M.V.⁵, Chagova R.M.⁶, Suslova I.R.⁷, Khryapa A.I.⁸, Lepshokova A.K.⁹, Fadeeva N.L.¹⁰, Safarova A.R.¹¹, Kaleykina L.P.¹², Lymar E.V.¹³, Chernyakova E.M.¹⁴, Snezhko O.A.⁹, Zinkovskaya A.E.¹⁵, Mufazalov F.F.¹⁶, Kuzmina E.S.¹⁷, Druzhinina Y.V.¹⁸, Musin S.I.¹⁶, Mukhitova M.R.¹¹, Khasanova A.I.¹¹, Safina S.Z.¹¹, Kirienko S.L.³
Affiliations:
1. A. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
2. National Medical Research Center for Endocrinology, Ministry of Health of Russia
3. Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
4. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
5. Moscow City Oncology Hospital No. 62, Moscow Healthcare Department
6. S.P. Botkin City Clinical Hospital, Moscow Healthcare Department
7. Oncological Dispensary No. 4, Moscow Healthcare Department
8. Saint Petersburg Clinical Scientific and Practical Center for Specialised Types of Medical Care (Oncological)
9. Oncological Dispensary of Rostov Region
10. S.G. Primushko Republican Clinical Oncologic Dispensary, Ministry of Health of the Udmurt Republic
11. Republican Clinical Oncological Dispensary, Ministry of Health of the Tatarstan
12. Republican Clinical Oncological Dispensary of the Republic of Mordovia
13. Clinical Oncology Dispensary No. 1, Ministry of Health of Krasnodar Region
14. Republican Oncological Dispensary of the Republic of Karelia
15. 5City Clinical Oncology Dispensary
16. Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan
17. Regional Cancer Center, Salekhard District Clinical Hospital
18. Multidisciplinary Clinical Medical Center “Medical City”
Issue: Vol 10, No 1 (2020)
Pages: 65-72
Section: ORIGINAL REPORT
Published: 11.04.2020
URL: https://ogsh.abvpress.ru/jour/article/view/478
DOI: https://doi.org/10.17650/2222-1468-2020-10-1-65-72
ID: 478

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Background. The implementation of tyrosine kinase inhibitors into clinical practice improved treatment outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for these patients.

The study objective is to analyze clinical experience with lenvatinib in patients with RR-DTC in the Russian Federation.

Materials and methods. The data from 18 clinical sites in Russia was analyzed for the period December 2015 and September 2019. Seventyseven patients with histologically verified DTC, proven resistance to radioactive iodine therapy, and tumor progression (according to the Response Evaluation Criteria In Solid Tumors 1.1 criteria) were included in the study.

Results.Median progression-free survival in patients included into analysis (n = 72) was 26.1 months. In patients who responded to therapy (including those with partial and complete response), median progression-free survival reached 36.2 months, which is higher than that reported in the updated results of the SELECT study (33.1 months). Lenvatinib-associated adverse events (AEs) were observed in 87 % of patients. Severe AEs were registered in 18.2 % of participants. In 6.5 % of cases, AEs lead to lenvatinib cessation; in 74 % of cases, AEs required dose reduction.

Conclusion. Our findings suggest high efficacy and good tolerability of lenvatinib in patients with RR-DTC in routine clinical practice in the Russian Federation.

Keywords

lenvatinib, radioiodine-refractory thyroid cancer, clinical practice, progression-free survival

References

Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2019. 236 c. [State of cancer care in Russia in 2018. Ed. by A.D. Kaprin, V.V. Starinsky, G.V. Petrova. Moscow, 2019. 236 р. (In Russ.)].
Румянцев П.О., Фомин Д.К., Румянцева У.В. Критерии радиойодрезистентности высокодифференцированного рака щитовидной железы к терапии радиоактивным йодом. Опухоли головы и шеи 2014;(3):4–9. [Rumyantsev P.O., Fomin D.K., Rumyantseva U.V. Сriteria of well-differentiated thyroid carcinoma resistance to radioiodine therapy. Opukholi golovy i shei = Head and Neck Tumors 2014;(3):4–9. (In Russ.)]. doi: 10.17650/2222-1468-2014-0-3-4-9.
Нечаева О.А., Бавыкина Л.Г., Древаль А.В. Дифференцированный рак щитовидной железы: современные подходы к диагностике, терапии и динамическому наблюдению (обзор). Русский медицинский журнал 2016;(1):9–12. [Nechaeva O.A., Bavykina L.G., Dreval A.V. Differentiated thyroid cancer: modern approaches to diagnosis, therapy and dynamic monitoring (review). Russky meditsinky zhurnal = Russian Medical Journal 2016;(1):9–12. (In Russ.)].
Brose M.S., Nutting C.M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319–28. doi: 10.1016/S0140-6736(14)60421-9.
Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30. doi: 10.1056/NEJMoa1406470.
Thyroid carcinoma. NCCN guidelines. Available at: NCCN v1.2019https://www. nccn.org/professionals/physician_gls/pdf/ thyroid.pdf.
Исаев П.А., Семин Д.Ю., Румянцев П.О. и др. Клинический опыт применения препарата ленвантиниб у пациентов с прогрессирующим дифференцированным раком щитовидной желез, рефрактерным к терапии радиоактивным йодом. Опухоли головы и шеи 2016;6(2):65–9. [Isaev P.A., Semin D.Y., Rumyantsev P.O. et al. Clinical experience in using lenvatinib in patients with progressive, radioactive iodine-refractory differentiated thyroid cancer. Opukholi golovy i shei = Head and Neck Tumors 2016;6(2):65–9. (In Russ.)]. doi: 10.17650/2222-1468-2016-6-2-65-69.
Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–47. DOI: 10.1016/j. ejca.2008.10.026.
Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Available at: https://www.eortc.be/services/doc/ctc/ CTCAE_4.03_2010-06-14_ QuickReference_5x7.pdf.
IBM SPSS Statistics. Available at: http:// www.predictive.ru/software/statistics.htm.
StatSoft. Available at: http://statsoft.ru.
Инструкция по медицинскому применению препарата ленватиниб. Регистрационный номер ЛП-003398 (с изменениями от 26.02.2019). Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2. aspx?routingGuid=114f1065-4daa-4dc49d0f-0ee1ee14377e&t= [Instruction on medical use of lenvatinib. Registration number ЛП-003398 (as amended on 26.02.2019). Available at: https://grls. rosminzdrav.ru/Grls_View_v2. aspx?routingGuid=114f1065-4daa-4dc49d0f-0ee1ee14377e&t= (In Russ.)].
Gianoukakis A.G., Dutcus C.E., Batty N. et al. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr Relat Cancer 2018;25(6): 699–704. doi: 10.1530/ERC-18-0049.

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register